Modality
Bispecific Ab
MOA
HER2
Target
GLP-1R
Pathway
RNA Splicing
HSOvarian CaHCC
Development Pipeline
Preclinical
Jan 2024
PreclinicalCurrent
NCT08820063
1,745 pts·HCC
2024-01→TBD·Not yet recruiting
1,745 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2024
Preclinical
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08820063 | Preclinical | HCC | Not yet recr... | 1745 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ |